[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656074":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":32,"interventions":39,"overallOfficials":25,"centralContacts":45,"locations":51,"responsibleParty":64,"collaborators":25,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":25,"enrollmentInfo":77,"targetDuration":25,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":25,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Objective response rate","Percentage of patients achieving complete response (CR) or partial response (PR), assessed according to RECIST version 1.1. Only evaluable patients for tumor response will be included in analysis.","At 4-week, 12-week after radiotherapy completion, then every 3 months up to 2-year follow-up or until disease progression\u002Fwithdrawal",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"2-year progression-free survival rate","Progression-free survival (PFS) is defined as the time from initiation of study treatment to documented disease progression (locoregional recurrence or distant metastasis) or death from any cause, whichever occurs first. The 2-year PFS rate is estimated by the Kaplan-Meier method. Imaging assessments are performed at 4 weeks and 12 weeks after radiotherapy completion, then every 3-months until disease progression, subject intolerance, withdrawal, or completion of 2-year follow-up.","From start of study treatment up to 24 months",{"measure":19,"description":20,"timeFrame":21},"2-year locoregional control rate","Locoregional control (LRC) is defined as the time from the start of study treatment until clinical or imaging-confirmed locoregional tumor recurrence (primary site or regional lymph nodes). Distant metastasis alone is not regarded as a locoregional control event. The 2-year locoregional control rate will be estimated using the Kaplan-Meier method. Tumor imaging assessments are performed at 4 weeks and 12 weeks after radiotherapy completion, then every 3 months until disease progression, subject intolerance, withdrawal, or completion of 2-year follow-up.","From start of study treatment through 2-year follow-up",{"measure":23,"description":24,"timeFrame":21},"Overall survival","Overall survival (OS) is defined as the time from initiation of study treatment to death from any cause. Patients who are alive will be censored at the end of 2-year follow-up. Survival status will be collected during regular follow-up visits.",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"NA","SINGLE_GROUP","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":25},"NONE",[33],{"label":34,"type":35,"description":36,"interventionNames":37},"Experimental: Nimotuzumab Combined with Radiotherapy","EXPERIMENTAL","Patients with locally advanced unresectable head-and-neck squamous cell carcinoma receive definitive intensity-modulated radiotherapy (IMRT) to the primary tumor and regional lymph nodes, concurrently with weekly intravenous nimotuzumab during the radiotherapy course. Tumor response is assessed by RECIST 1.1 and adverse events are graded by CTCAE v5.0.",[38],"Drug: Nimotuzumab",[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":25},"DRUG","Nimotuzumab","Humanized anti-EGFR monoclonal antibody, administered by intravenous infusion once weekly during the whole radiotherapy period.",[34],[46],{"name":47,"role":48,"phone":49,"phoneExt":25,"email":50},"Ke Hu","CONTACT","010-69154011","huk@pumch.cn",[52],{"facility":5,"status":25,"city":53,"state":25,"zip":25,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Beijing","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":47,"role":48,"phone":49,"phoneExt":25,"email":50},{"type":65,"investigatorFullName":47,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Attending Physician","100656074","phase-2-nimotuzumab-plus-radiotherapy-in-elderly-patients-with-locally-advanced-head-and-neck-squamous-cell-carcinoma-100656074",false,"NCT07821242","Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined With Radiotherapy for Elderly Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","NCRHNC","Inclusion Criteria:\n\n1. Age ≥ 65 years old.\n2. Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of head and neck (oral cavity, oropharynx, larynx, hypopharynx).\n3. Positive EGFR test result in tumor tissue.\n4. Tumor tissue available for HPV \u002F P16 testing; no repeated testing required if prior test results are already available.\n5. ECOG performance status 0-2 OR KPS score ≥ 60.\n6. Patients who are assessed to be intolerant to chemotherapy or refuse chemotherapy.\n7. At least one measurable lesion according to RECIST version 1.1.\n8. Estimated life expectancy ≥ 6 months.\n9. Adequate hematological function: white blood cell count ≥4×10\\^9\u002FL; absolute neutrophil count ≥1.5×10\\^9\u002FL; platelet count ≥100×10\\^9\u002FL; hemoglobin ≥90 g\u002FL.\n10. Adequate renal function: serum creatinine ≤1.5×ULN OR creatinine clearance (CrCl) \\>60 mL\u002Fmin calculated by Cockcroft-Gault formula.\n11. Adequate hepatic function: total bilirubin ≤1.5×ULN; AST ≤2.5×ULN; ALT ≤2.5×ULN.\n12. Voluntarily sign written informed consent form and be able to comply with protocol-required visits and procedures.\n\nExclusion Criteria:\n\n1. Age ≥ 65 years old.\n2. Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of head and neck (oral cavity, oropharynx, larynx, hypopharynx).\n3. Positive EGFR test result in tumor tissue.\n4. Tumor tissue available for HPV \u002F P16 testing; no repeated testing required if prior test results are already available.\n5. ECOG performance status 0-2 OR KPS score ≥ 60.\n6. Patients who are assessed to be intolerant to chemotherapy or refuse chemotherapy.\n7. At least one measurable lesion according to RECIST version 1.1.\n8. Estimated life expectancy ≥ 6 months.\n9. Adequate hematological function: white blood cell count ≥4×10\\^9\u002FL; absolute neutrophil count ≥1.5×10\\^9\u002FL; platelet count ≥100×10\\^9\u002FL; hemoglobin ≥90 g\u002FL.\n10. Adequate renal function: serum creatinine ≤1.5×ULN OR creatinine clearance (CrCl) \\>60 mL\u002Fmin calculated by Cockcroft-Gault formula.\n11. Adequate hepatic function: total bilirubin ≤1.5×ULN; AST ≤2.5×ULN; ALT ≤2.5×ULN.\n12. Voluntarily sign written informed consent form and be able to comply with protocol-required visits and procedures.","ALL","65 Years",{"count":78,"type":79},46,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This is a prospective, single-center, open-label, single-arm phase II study. The purpose of this study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy (IMRT) in elderly patients (≥65 years old) with locally advanced unresectable head-and-neck squamous cell carcinoma (HNSCC) who are unfit for standard concurrent cisplatin-based chemoradiotherapy. Eligible patients will receive standard-dose intensity-modulated radiotherapy together with weekly nimotuzumab. The primary endpoint is 1-year overall survival rate. Secondary endpoints include progression-free survival, objective tumor response rate, locoregional control rate, distant metastasis rate, and treatment-related adverse events. Patients will be followed up for survival, tumor status and safety assessments after treatment completion.",[85,86],"Head & Neck Cancer","Radiotherapy","NOT_YET_RECRUITING","2026-09-10",{"date":90,"type":91},"2026-09-15","ACTUAL",{"date":88,"type":79},{"date":94,"type":79},"2029-03-23",{"name":47,"class":6},1]